Patents by Inventor Andreas Petri

Andreas Petri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treatment using antisense oligomers and conjugates targeting PCSK9
    Patent number: 10385342
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 20, 2019
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Manufacture of antisense oligomers and conjugates targeting PCSK9
    Patent number: 10370668
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 6, 2019
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Targeting human satellite II (HSATII)
    Patent number: 10301624
    Abstract: Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides. As shown herein, the hetero chromatic HSATII satellite repeat is silenced in normal cells, but massively over expressed in epithelial cancers and in cancer cell lines when grown as xenografts or in 3D culture. Induction of HSATII RNA, either in xenografts or using in vitro reconstitution models, suggests the appearance of complementary DNA intermediates.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 28, 2019
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Francesca Bersani, Anders M. Naar, Mihir Shivadatta Rajurkar, Sakari Kauppinen, Andreas Petri
  • KETOREDUCTASES
    Publication number: 20190062714
    Abstract: The invention relates to ketoreductases and the use thereof. The ketoreductases of the invention are particularly useful for enzymatically catalyzing the reduction of ketones to chiral secondary alcohols.
    Type: Application
    Filed: August 30, 2018
    Publication date: February 28, 2019
    Applicant: C-LEcta GmbH
    Inventors: Ramona Schmiedel, Andreas Vogel, Sabrina Koepke, Rico Czaja, Claudia Feller, Hedda Merkens, Kamila Rzeznicka, Daniel Schwarze, Thomas Greiner-Stoeffele, Andreas Petri, Marc Struhalla
  • Manufacture of Antisense Oligomers and Conjugates Targeting PCSK9
    Publication number: 20180312846
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 1, 2018
    Inventors: Nanna ALBÆK, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Methods of Treatment Using Antisense Oligomers and Conjugates Targeting PCSK9
    Publication number: 20180312847
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 1, 2018
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie Wickstrom LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • Ketoreductases
    Patent number: 10093905
    Abstract: The invention relates to ketoreductases and the use thereof. The ketoreductases of the invention are particularly useful for enzymatically catalyzing the reduction of ketones to chiral secondary alcohols.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: October 9, 2018
    Assignee: C-LEcta GmbH
    Inventors: Ramona Schmiedel, Andreas Vogel, Sabrina Koepke, Rico Czaja, Claudia Feller, Hedda Merkens, Kamila Rzeznicka, Daniel Schwarze, Thomas Greiner-Stoeffele, Andreas Petri, Marc Struhalla
  • ANTISENSE OLIGOMERS AND CONJUGATES TARGETING PCSK9
    Publication number: 20180216116
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: December 8, 2017
    Publication date: August 2, 2018
    Inventors: Nanna Albaek, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Oligonucleotide conjugates
    Patent number: 9879265
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 30, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • KETOREDUCTASES
    Publication number: 20170218345
    Abstract: The invention relates to ketoreductases and the use thereof. The ketoreductases of the invention are particularly useful for enzymatically catalyzing the reduction of ketones to chiral secondary alcohols.
    Type: Application
    Filed: April 17, 2015
    Publication date: August 3, 2017
    Applicants: C-LEcta GmbH, C-LEcta GmbH
    Inventors: Ramona Schmiedel, Andreas Vogel, Sabrina Koepke, Rico Czaja, Claudia Feller, Hedda Merkens, Kamila Rzeznicka, Daniel Schwarze, Thomas Greiner-Stoeffele, Andreas Petri, Marc Struhalla
  • OLIGONUCLEOTIDE CONJUGATES
    Publication number: 20160138025
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: June 27, 2014
    Publication date: May 19, 2016
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
    Patent number: 9034837
    Abstract: The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: May 19, 2015
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Elisabeth S. Hildebrandt-Eriksen, Andreas Petri, Sakari Kauppinen, Niels Abrahamsen, Robert Eldon Lanford
  • Lipolytic enzyme variants
    Patent number: 8679774
    Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: March 25, 2014
    Assignee: Novozymes A/S
    Inventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schroder Glad, Gitte Budolfsen
  • Pharmaceutical Compositions for Treatment of HCV Patients that are Poor-Responders to Interferon
    Publication number: 20100330035
    Abstract: The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.
    Type: Application
    Filed: April 26, 2010
    Publication date: December 30, 2010
    Inventors: Elisabeth S. HILDEBRANDT-ERIKSEN, Andreas Petri, Sakari Kauppinen, Niels Abrahamsen, Robert Eldon Lanford
  • Lipolytic enzyme variants
    Patent number: 7851176
    Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: December 14, 2010
    Assignee: Novozymes A/S
    Inventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schroder Glad, Gitte Budolfsen
  • Lipolytic Enzyme Variants
    Publication number: 20100291262
    Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.
    Type: Application
    Filed: August 4, 2010
    Publication date: November 18, 2010
    Applicant: Novozymes A/S
    Inventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schroder Glad, Gitte Budolfsen
  • Lipolytic enzyme variants
    Patent number: 7632669
    Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: December 15, 2009
    Assignee: Novozymes A/S
    Inventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schroder Glad, Gitte Budolfsen
  • LIPOLYTIC ENZYME VARIANTS
    Publication number: 20090047384
    Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.
    Type: Application
    Filed: October 3, 2008
    Publication date: February 19, 2009
    Applicant: Novozymes A/S
    Inventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schroder Glad, Gitte Budolfsen
  • Lipolytic Enzyme Variants
    Publication number: 20080131951
    Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.
    Type: Application
    Filed: December 6, 2007
    Publication date: June 5, 2008
    Applicant: Novozymes A/S
    Inventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schroder Glad, Gitte Budolfsen
  • Lipolytic enzyme variants
    Patent number: 7312062
    Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: December 25, 2007
    Assignee: Novozymes A/S
    Inventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schrøder Glad, Gitte Budolfsen